Dermatology

Multiple animal models are used in preclinical product development including:

• Gene knockout/knockin/trapped
• Transgenic rodents
• Chemically-Induced Point Mutation rodents
• Stress-induced models
• Drug-Induced models
• Wound/Laceration Models
• Metabolically-induced models (Diet-induced, Metabolic disorder, micronutrient deficient)
• And more…

We conduct translational animal studies (in vivo and in vitro) collecting detailed, comprehensive results with rapid turnaround.

Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

At AniLocus, we conduct relevant preclinical studies to assess any drug modality:

• Antibodies (nanobodies, monoclonal)
• Gene therapy (CRISPR, TALEN)
• Viral therapy (adenovirus-AAV, lentivirus)
• Oligo- and polypeptides (e.g., stapled and modified peptides)
• Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
• Polyglycosides
• Macrocyclic molecules
• Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
• Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
• Cellular therapies (stem cells, allogenic, autologous)

Using animal and human cells and tissue we can perform multiple interrogative assays depending on therapeutic area and sample type:

• DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
• RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
• Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
• And more!

1. Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153(5):406–412. doi:10.1001/jamadermatol.2016.5538. < https://jamanetwork.com/journals/jamadermatology/fullarticle/2604831 >.
2. Therdpong Tempark, Khwaunrat Whaidee, Chansuda Bongsebandhu-phubhakdi, Orapa Suteerojntrakool, Prevalence of skin diseases in school-age children, Family Practice, Volume 39, Issue 3, June 2022, Pages 340–345. < https://doi.org/10.1093/fampra/cmab164 >.
3. Svensson, A., Ofenloch, R. F., Bruze, M., Naldi, L., Cazzaniga, S., Elsner, P., Goncalo, M., Schuttelaar, M. A., & Diepgen, T. L. (2018). Prevalence of skin disease in a population-based sample of adults from five European countries. The British journal of dermatology, 178(5), 1111–1118. < https://doi.org/10.1111/bjd.16248 >.
4. Wang, C., Strasinger, C., Shen, M., & Tsong, Y. (2020). Statistical Considerations in Assessing In Vivo Adhesion with Transdermal and Topical Delivery Systems for New Drug Applications. The AAPS journal, 22(6), 137. < https://doi.org/10.1208/s12248-020-00519-z >.
5. Schön, M. P., Manzke, V., & Erpenbeck, L. (2021). Animal models of psoriasis-highlights and drawbacks. The Journal of allergy and clinical immunology, 147(2), 439–455. < https://doi.org/10.1016/j.jaci.2020.04.034 >.
6. Lewis, B., & Branch, D. R. (2020). Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics. Pharmacology, 105(11-12), 618–629. < https://doi.org/10.1159/000508239 >.